Progress toward an antitumor vaccine
How can we induce the body to use its own weapon, the immune system, to battle cancer" In principle, by the same means used against infectious diseases: immunization. The production of a selective vaccine is not a trivial task, however. A team led by Horst Kunst at the University of Mainz has now found a way to bind a molecule that is typical for tumors to a carrier protein without irritating...
Benzotiophene derivatives exhibit antitumor activity
Raquel Villar Becares, Ph.D, student at Public University of Navarre has reported in her thesis that benzo[b]tiophene 1,1 dioxide is found to have anti-cancer effects//. She tested 24 compounds isolated from the derivatives and found 23 compounds from it had
antitumor activity when tested in invitro cell cultures. Initial studies have found that the benzotiophene derivatives have antitumo...
Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Quadramet at International Myeloma Workshop
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CytogenCorporation (NASDAQ: CYTO) reported updated data from a Phase 1dose escalation study evaluating QUADRAMET(R) (samarium Sm-153lexidronam injection) in combination with bortezomib (Velcade(R),Millennium Pharmaceuticals, Inc.) in patients with relapsedmultiple myeloma. Data from 33 patients were presented today in aposter titled, "Phase 1...
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
Clinical Benefit Shown in 35% of HER2-Positive Metastatic BreastCancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that alvespimycin, its second-generation Hsp90inhibitor, demonstrated promising
antitumor activity andtolerability in combination with trastuzumab (Herceptin(R)) inpatient...
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Epothilone KOS-1584 at ASCO
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that KOS-1584/R1645, an epothilone underco-development with Roche, demonstrated promising
antitumoractivity and tolerability in patients with solid tumors.KOS-1584/R1645 showed activity in 32% of patients (13 of 41evaluable) including activity in pati...
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a dose-escalatingPhase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin(KOS-953) in combination with bortezomib (Velcade(R)), showing ahigh degree of
antitumor activity and tolerability in patients withmult...
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented preliminary data from a Phase 2monotherapy trial showing that tanespimycin demonstrated
antitumoractivity and tolerability in patients with metastatic melanoma,including one patient with a BRAF mutation (V600E) who had failedprior chemotherapy (within 6 weeks of initiation) and while ontanesp...
More>>